Nobivac® Lepto4




Canine Class

>Vaccines – 1-year immunity

Nobivac® Lepto4

Biological name
Leptospira Canicola, Grippotyphosa, Icterohaemorrhagiae, Pomona Bacterin

The first and only canine vaccine specifically indicated to protect against disease and mortality and leptospiruria (urinary shedding).

Features and benefits

  • Prevented mortality caused by 4 virulent Leptospira serovars1
  • Prevents liver dysfunction and thrombocytopenia1
  • The only vaccine indicated to protect against mortality and leptospiruria
  • Significantly reduced leptospiremia1
  • Proven safe and well tolerated in multiple studies1
  • Available in both a monovalent and combination formulation


  • Indicated to aid in the prevention of disease and mortality caused by L. canicola, L. icterohaemorrhagiae, L. pomona, or L. grippotyphosa
  • Prevents leptospiruria associated with L. grippotyphosa, L. canicola, or L. icterohaemorrhagiae
  • Aids in the prevention of leptospiruria associated with L. pomona
  • Recommended for use in healthy dogs 8 weeks of age or older

Safety information

  • Safety confirmed in a 749-dog field study1
  • Well tolerated on subcutaneous administration
  • Proven safe across a variety of breeds and ages
  • Now featuring an even higher level of quality due to the new VacciPure™ filtration

Dosage and administration

  • Subcutaneous injection
  • Two 1-mL doses given 2 to 4 weeks apart
  • Last dose may be given at 12 weeks of age
  • Annual revaccination with 1 dose is recommended
  • Available in a 25 x 1-mL dose

For further information, including complete directions and warnings, please see the product label.

Product label(s) and MSDS


1. Data on file, Merck Animal Health.

TRUSTe European Safe Harbor certification
Validate TRUSTe privacy certification